PET-directed therapy in Hodgkin lymphoma: Ready for prime time?

Research output: Contribution to journalReview articlepeer-review


Advances in chemotherapy and radiation therapy have allowed the vast majority of patients with Hodgkin lymphoma to be cured, but some of these patients develop treatment-related complications, including second malignancies, cardiovascular disease, and thyroid disease. Efforts to decrease exposure of patients to more chemotherapy or radiation therapy than is necessary to cure their disease have led to a trend toward shortened treatment regimens in patients with low-risk disease. Predicting which patients will relapse, and therefore might benefit from a more intense treatment regimen, has been a clinical challenge. PET has emerged as a useful modality in the diagnosis and management of Hodgkin lymphoma, and has been studied as a potential tool to help the oncologist to utilize the optimal chemotherapy and radiation therapy regimen for each patient.

Original languageEnglish (US)
Pages (from-to)1431-1441
Number of pages11
JournalExpert review of anticancer therapy
Issue number12
StatePublished - Dec 2 2015


  • Hodgkin lymphoma
  • PET-directed
  • adriamycin
  • bleomycin
  • dacarbazine
  • deauville criteria
  • vinblastine

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'PET-directed therapy in Hodgkin lymphoma: Ready for prime time?'. Together they form a unique fingerprint.

Cite this